Literature DB >> 20367208

Brain metastases: a medical neuro-oncology perspective.

Marc C Chamberlain1.   

Abstract

Brain metastases (BMs) are the most common neurological complication related to cancer. A review of recent and relevant literature relating to BMs was performed and found that the therapy of BMs remains controversial, notwithstanding numerous randomized clinical trials. Surgical resection of a solitary BM when possible, followed by whole-brain irradiation (WBI) is an established standard of care. More controversial is the substitution of stereotactic radiosurgery for surgery in the treatment of solitary BM. Treatment with WBI following local therapy remains controversial, with advocates for and against WBI. At present, systemic chemotherapy for BMs offers only very modest palliation. In summary, treatment of BMs remains contentious with respect to the utilization and timing of surgical resection, application of WBI and stereotactic radiosurgery, notwithstanding numerous randomized trials, as the range of interpretation of these trials has resulted in differing treatment perspectives.

Entities:  

Mesh:

Year:  2010        PMID: 20367208     DOI: 10.1586/ern.10.30

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

1.  Medical oncology: Patients with brain metastases in early-phase trials.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Nat Rev Clin Oncol       Date:  2011-05-17       Impact factor: 66.675

2.  Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience.

Authors:  Apostolia Maria Tsimberidou; Katherine Letourneau; Sijin Wen; Jennifer Wheler; David Hong; Aung Naing; Nancy G Iskander; Cynthia Uehara; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

Review 3.  The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis.

Authors:  Ashhar S Ali; Aamir Ahmad; Shadan Ali; Bin Bao; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2013-01       Impact factor: 6.384

4.  Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China.

Authors:  Yang Wang; Bin Lian; Lu Si; ZhiHong Chi; XiNan Sheng; Xuan Wang; LiLi Mao; BiXia Tang; SiMing Li; XieQiao Yan; Xue Bai; Li Zhou; ChuanLiang Cui; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-21       Impact factor: 4.553

5.  Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis.

Authors:  Meng Qian; Michelle W Ma; Nathaniel H Fleming; Daniel J Lackaye; Eva Hernando; Iman Osman; Yongzhao Shao
Journal:  Melanoma Res       Date:  2013-12       Impact factor: 3.599

6.  Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site.

Authors:  Michelle W Ma; Meng Qian; Daniel J Lackaye; Russell S Berman; Richard L Shapiro; Anna C Pavlick; John G Golfinos; Erik C Parker; Farbod Darvishian; Eva Hernando; Yongzhao Shao; Iman Osman
Journal:  Neuro Oncol       Date:  2012-05-03       Impact factor: 12.300

7.  Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Authors:  Geoffrey T Gibney; Geneviève Gauthier; Charles Ayas; Philip Galebach; Eric Q Wu; Sarang Abhyankar; Carolina Reyes; Annie Guérin; Yeun Mi Yim
Journal:  Cancer Med       Date:  2015-05-20       Impact factor: 4.452

8.  The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.

Authors:  Enda J Hannan; Donal P O'Leary; Stephen P MacNally; Elaine W Kay; Michael A Farrell; Patrick G Morris; Colm P Power; Arnold D K Hill
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event.

Authors:  D R Brown; R Lanciano; C Heal; A Hanlon; J Yang; J Feng; M Stanley; R Buonocore; A Okpaku; W Ding; S Arrigo; J Lamond; L Brady
Journal:  J Radiat Oncol       Date:  2016-12-06

10.  Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature.

Authors:  Shaharyar Ahmad; Anthony Ricco; Royce Brown; Alexandra Hanlon; Jun Yang; Jing Feng; Michael Stanley; Richard Buonocore; Aubrey Okpaku; Steven Arrigo; John Lamond; Luther Brady; Rachelle Lanciano
Journal:  Front Oncol       Date:  2017-03-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.